SHORTList
NewLimit logo
AI/ML
Biotech/Pharma

NewLimit

Biotechnology for extending human healthspan

South San Francisco· 15 roles

CORE INFO

$435M
Total Funding
Series C
Round
2021
Founded
11-50
Team Size
South San Francisco, California, USA
Headquarters

NewLimit is a biotechnology company that develops therapies to reverse cellular aging, targeting the liver, immune system, and vasculature to enhance metabolism and cognition in later life. Their AI-driven discovery engine integrates genomics and machine learning to identify effective therapeutic candidates.

  • Series C funding round raised $435 million, led by Founders Fund with participation from Thrive Capital, Greenoaks, and Quiet Capital.lw.com
  • TechCrunch reported on NewLimit's Series B funding of $130 million, highlighting its focus on developing age-reversing therapies.techcrunch.com

WHY WE WOULD WORK AT NEWLIMIT

Transform Lives

Join a mission-driven team dedicated to extending human healthspan through innovative epigenetic reprogramming therapies that aim to reverse cellular aging.

Cutting-Edge Technology

Work with advanced technologies like functional genomics and machine learning, positioning NewLimit at the forefront of biotechnology and age-related disease treatment.

Strong Financial Backing

Benefit from substantial funding of $435 million, ensuring resources for groundbreaking research and development in healthspan extension.

Top Talent Environment

Collaborate with a diverse team of top-tier professionals, including leaders from biotech and tech industries, fostering an atmosphere of innovation and excellence.

Impactful Work

Contribute to pioneering therapies targeting critical areas like the liver and immune system, directly addressing diseases that mimic accelerated aging.

Growth Opportunities

Experience professional development in a rapidly growing company valued at $3.1 billion, with ample opportunities to advance your career in biotechnology.

MARKET AND TRACTION

TOTAL ADDRESSABLE MARKET

  • NewLimit operates in the biotechnology sector, specifically targeting age-related diseases and healthspan extension.

  • The market for therapies aimed at reversing cellular aging is rapidly growing, driven by an increasing aging population and demand for longevity solutions.

    • KEY METRICS

    ✦ KEY METRIC
  • Total funding raised by NewLimit amounts to $435 million across multiple funding rounds.

  • The company's most recent funding round, Series C, raised $435 million in June 2026, valuing NewLimit at approximately $3.1 billion.

    • GROWTH TACTICS

  • NewLimit employs an interdisciplinary approach, combining biotechnology and computer science to develop innovative therapies.

  • The company focuses on leveraging advanced technologies like functional genomics and machine learning to enhance its research and development capabilities.

    • COMPETITIVE ADVANTAGE

  • NewLimit's unique focus on epigenetic reprogramming therapies sets it apart in the biotechnology field.

  • The company's leadership team includes experienced founders from notable tech and biotech backgrounds, enhancing its credibility and innovation potential.

    • MARKET POSITION

  • NewLimit is positioned as a leader in the emerging field of epigenetic therapies aimed at extending healthspan.

  • The company has successfully attracted significant investment, indicating strong market confidence in its mission and technology.

    • PRODUCT AND TECH

    Epigenetic Reprogramming Therapies

    NewLimit develops innovative therapies that aim to reverse cellular aging by reprogramming the epigenome, restoring youthful function in aged cells. These therapies target critical areas such as the liver, immune system, and vasculature to address diseases that mimic accelerated aging.

    Functional Genomics

    The company employs functional genomics to study the genetic factors influencing aging and cellular function. This technology is crucial for identifying potential therapeutic targets and understanding the mechanisms behind age-related diseases.

    Machine Learning Models

    NewLimit utilizes machine learning models to analyze complex biological data, enhancing the development of epigenetic therapies. This approach allows for more precise predictions and optimizations in the therapeutic design process.

    Pooled Perturbation Screening

    This methodology is used by NewLimit to systematically test the effects of various genetic modifications on cellular aging. Pooled perturbation screening helps identify key pathways and targets for therapeutic intervention.

    Therapeutic Programs

    NewLimit's initial therapeutic programs focus on critical health areas, including liver health and immune function, aiming to develop treatments that can significantly enhance healthspan and combat age-related diseases.

    COMPANY CULTURE

    Values

  • Inherent Optimism: Pursuing ambitious goals with a truthful perspective.

  • Mission Focused: Creating an environment dedicated to advancing their mission of extending human healthspan.

  • Clear Communication: Emphasizing concise, clear, and kind communication.

  • Independent Thinking: Making decisions based on internal conclusions, even amid criticism.

  • Top Talent in Every Seat: Hiring and developing the best talent from diverse backgrounds.

  • Safety, Then Speed: Prioritizing safety before swift execution.

    • Operating Principles

  • Everyone Executes: Ensuring all roles contribute to daily execution without pure management positions.

  • Revenue Focus: Building a for-profit company as a strategic component to achieve their mission.

  • Collaborative Innovation: Encouraging interdisciplinary collaboration between biotechnology and computer science.

    • Benefits

  • Competitive salary and equity options to attract top talent.

  • Opportunities for professional development and growth in a cutting-edge field.

  • A mission-driven work environment that fosters a sense of purpose and impact.

    • Team Cadence

  • Regular team meetings to align on goals and progress.

  • Open feedback culture to encourage continuous improvement.

  • Flexible work arrangements to support work-life balance.

    • Learning & Growth

  • Commitment to ongoing education and training in biotechnology advancements.

  • Access to industry conferences and workshops for professional development.

  • Mentorship programs to foster talent development and knowledge sharing.

    • COMPENSATION SNAPSHOT

    Cohort too small to score (n < 5). Per-role bands shown below.
    Based on publicly available compensation ranges from job postings; exact compensation may vary.
    Datan = 3
    $130K – $171Kmedian $151K
    Los Angeles / Bay Area
    Engineering IC3n = 3
    $75K – $100Kmedian $88K
    Los Angeles / Bay Area
    US-only in v1 · only categories with n > 2 shown · in-person / hybrid / remote treated separately where n ≥ 3

    HIRING SIGNAL

    15
    Open roles on their careers page
    Snapshot via live ATS poll
    —
    Net new roles in the last 90 days
    Available once weekly history accrues
    90-Day VelocityV2 · BACKFILL
    Trend builds weekly as historical rows accrue
    By Function
    Breakdown of open roles
    Other · 3
    Design · 1
    G&A · 1
    Operations · 2
    Engineering · 8
    Top Locations
    Where hiring is concentrated
    Remote-eligible postings counted separately
    South San Francisco
    11
    South San Francisco, CA
    4
    SourcesGreenhouseLeverAshbyWorkableSmartRecruitersRipplingRecruiteeFallback · Wellfound, YC Work-at-a-Startup, careers-page scrape

    KEY COMPANY ANNOUNCEMENTS

    Filter
    8 announcements · ranked by importance
    Jun 4, 2026FUNDINGLatham Watkins Advises NewLimit on Series Clw.com
    May 15, 2025FUNDINGForm D filing — NewLimit, Inc. (CIK 0001977037)sec.gov
    May 1, 2025FUNDINGNewLimit raises $130 million Series B led by Kleiner Perkins alongside NFDG, Khosla Ventures, Human Capital and othersblog.newlimit.com
    Jan 7, 2025FUNDINGForm D filing — NewLimit, Inc. (CIK 0001977037)sec.gov
    May 17, 2023FUNDINGForm D filing — NewLimit, Inc. (CIK 0001977037)sec.gov
    May 16, 2023FUNDINGNewLimit secures $40 million in venture funding from Dimension Capital, Founders Fund, Kleiner Perkins and other investorsblog.newlimit.com
    May 16, 2023FUNDINGNewLimit, co-founded by Coinbase CEO Brian Armstrong, raises $40M to extend life | TechCrunchtechcrunch.com
    Dec 12, 2021FOUNDER PROFILENewLimit: a company built to extend human healthspanblog.newlimit.com